Market News AIOpen the app

CGEM stock news · Cullinan Therapeutics, Inc.

Stories about Cullinan Therapeutics, Inc. (CGEM) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CGEM

Follow Cullinan Therapeutics, Inc. (CGEM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CGEM
Free on the App Store and Google Play, or on the web.
  1. Nov 4, 2026, 9:27 AM ET · Market

    Cullinan Therapeutics shared new information about its CLN-049 trial ahead of the American Society of Hematology meeting.

    Good for CGEM

    Cullinan reported a 45% overall response rate at the 12 μg/kg dose and a 26% cytokine reaction rate in a two-step dosing group. These early findings favor its drug program.

  2. Sep 24, 2026, 7:38 AM ET · Market

    Cullinan Therapeutics, Inc. says it will share key clinical trial information in late 2026.

    Neutral

    Cullinan set dates to present multiple Phase 1 data items in Nov and Dec, but the filing contains no results, so it does not change how I read Cullinan today.

  3. Aug 13, 2026, 11:28 AM ET · Trial

    Key Phase 3 milestone achieved as Cullinan Therapeutics' zipalertinib combination emerges as a viable first-line treatment for lung cancer.

    Good for CGEM

    Cullinan Therapeutics has reported positive interim results from its Phase 3 trial of zipalertinib, showing significant improvement in progression-free survival for lung cancer patients. This breakthrough could position zipalertinib as a leading treatment option, potentially driving stock prices up as investors react to the favorable data.